Author details

Full Name

Jack F Shern

Affiliation

ORCID

Career Start Year

2001

Papers

H Index

Expertise

CM4AI Collaborator

PMID	Paper Title	Journal Title	Published Year
37889049	Childhood cancer data initiative: Status report.	Pediatr Blood Cancer	2024
36658307	Urine cell-free DNA multi-omics to detect MRD and predict survival in bladder cancer patients.		2023
36302175	A Phase II Trial of Guadecitabine in Children and Adults with SDH-Deficient GIST, Pheochromocytoma, Paraganglioma, and HLRCC-Associated Renal Cell Carcinoma.	Clin Cancer Res	2023
36346688	Predicting Molecular Subtype and Survival of Rhabdomyosarcoma Patients Using Deep Learning of H&E Images: A Report from the Children's Oncology Group.	Clin Cancer Res	2023
36322002	The Combination of Trametinib and Ganitumab is Effective in RAS-Mutated PAX-Fusion Negative Rhabdomyosarcoma Models.	Clin Cancer Res	2023
37585199	Estimated Prevalence, Tumor Spectrum, and Neurofibromatosis Type 1-Like Phenotype of CDKN2A-Related Melanoma-Astrocytoma Syndrome.	JAMA Dermatol	2023
37910044	Cooperative armoring of CAR and TCR T-cells by T cell-restricted IL-15 and IL-21 universally enhances solid tumor efficacy.		2023
37781575	MYCN driven oncogenesis involves cooperation with WDR5 to activate canonical MYC targets and G9a to repress differentiation genes.		2023
37616468	Inhibition of NAD+-Dependent Metabolic Processes Induces Cellular Necrosis and Tumor Regression in Rhabdomyosarcoma Models.	Clin Cancer Res	2023
37398992	Phase I trial of Ganitumab plus Dasatinib to Cotarget the Insulin-Like Growth Factor 1 Receptor and Src Family Kinase YES in Rhabdomyosarcoma.	Clin Cancer Res	2023
37267580	The Childhood Cancer Data Initiative: Using the Power of Data to Learn From and Improve Outcomes for Every Child and Young Adult With Pediatric Cancer.	J Clin Oncol	2023
37167059	Protocol for using single-cell sequencing to study the heterogeneity of NF1 nerve sheath tumors from clinical biospecimens.		2023
36724417	Circulating Tumor DNA Is Prognostic in Intermediate-Risk Rhabdomyosarcoma: A Report From the Children's Oncology Group.	J Clin Oncol	2023
36598365	HAND2 Assists MYCN Enhancer Invasion to Regulate a Noradrenergic Neuroblastoma Phenotype.		2023
34840249	Liquid biopsies in pediatric oncology: opportunities and obstacles.	Current Opinion in Pediatrics	2022
36243768	Loss of CASZ1 tumor suppressor linked to oncogenic subversion of neuroblastoma core regulatory circuitry.	Cell Death and Disease	2022
35839732	Molecular testing of rhabdomyosarcoma in clinical trials to improve risk stratification and outcome: A consensus view from European paediatric Soft tissue sarcoma Study Group, Children's Oncology Group and Cooperative Weichteilsarkom-Studiengruppe.	Eur J Cancer	2022
35802683	Anti-GD2 Antibodies Conjugated to IL15 and IL21 Mediate Potent Antitumor Cytotoxicity against Neuroblastoma.	Clinical Cancer Research	2022
36134665	Multiple Nf1 Schwann cell populations reprogram the plexiform neurofibroma tumor microenvironment.	JCI insight	2022
36130486	Single-cell sequencing reveals activation of core transcription factors in PRC2-deficient malignant peripheral nerve sheath tumor.	Cell Reports	2022
35253347	Cutaneous mosaic RASopathies associated with rhabdomyosarcoma.	Pediatric Blood and Cancer	2022
34818552	Immuno-transcriptomic profiling of extracranial pediatric solid malignancies.	Cell Rep	2021
33591953	Chromosome 8 gain is associated with high-grade transformation in MPNST.	JCI Insight	2021
34010628	Stem-like cells drive NF1-associated MPNST functional heterogeneity and tumor progression.		2021
34166228	Serine hydroxymethyltransferase 2 expression promotes tumorigenesis in rhabdomyosarcoma with 12q13-q14 amplification.	J Clin Invest	2021
34166060	Genomic Classification and Clinical Outcome in Rhabdomyosarcoma: A Report From an International Consortium.	J Clin Oncol	2021
33848174	Neopetrothiazide: An Intriguing Pentacyclic Thiazide Alkaloid from the Sponge <i>Neopetrosia</i> sp.	Org Lett	2021
33915882	Prioritization of Novel Agents for Patients with Rhabdomyosarcoma: A Report from the Children's Oncology Group (COG) New Agents for Rhabdomyosarcoma Task Force.	J Clin Med	2021
33708626	Defining the Extracellular Matrix of Rhabdomyosarcoma.	Front Oncol	2021
33302115	The prognostic significance of anaplasia in childhood rhabdomyosarcoma: A report from the Children's Oncology Group.	Eur J Cancer	2021
34680895	Genetic Characterization, Current Model Systems and Prognostic Stratification in PAX Fusion-Negative vs. PAX Fusion-Positive Rhabdomyosarcoma.	Genes (Basel)	2021
34464388	Cell-free DNA ultra-low-pass whole genome sequencing to distinguish malignant peripheral nerve sheath tumor (MPNST) from its benign precursor lesion: A cross-sectional study.	PLoS Med	2021
33246985	Diagnostic approach to the evaluation of myeloid malignancies following CAR T-cell therapy in B-cell acute lymphoblastic leukemia.	J Immunother Cancer	2020
32182803	The Role of Polycomb Repressive Complex in Malignant Peripheral Nerve Sheath Tumor.	Genes	2020
32060262	CASZ1 induces skeletal muscle and rhabdomyosarcoma differentiation through a feed-forward loop with MYOD and MYOG.	Nat Commun	2020
32103145	Serial evaluation of CD19 surface expression in pediatric B-cell malignancies following CD19-targeted therapy.	Leukemia	2020
33151696	Denigrins and Dactylpyrroles, Arylpyrrole Alkaloids from a <i>Dactylia</i> sp. Marine Sponge.	J Nat Prod	2020
32703985	Transcriptome analysis of desmoplastic small round cell tumors identifies actionable therapeutic targets: a report from the Children's Oncology Group.	Sci Rep	2020
32925169	Perforin-deficient CAR T cells recapitulate late-onset inflammatory toxicities observed in patients.	J Clin Invest	2020
31054580	Exogenous expression of the glycosyltransferase LARGE1 restores Î±-dystroglycan matriglycan and laminin binding in rhabdomyosarcoma.	Skelet Muscle	2019
31784732	Histone hyperacetylation disrupts core gene regulatory architecture in rhabdomyosarcoma.	Nat Genet	2019
30565669	Relationship of DNA methylation to mutational changes and transcriptional organization in fusion-positive and fusion-negative rhabdomyosarcoma.	Int J Cancer	2019
31285436	Chemical genomics reveals histone deacetylases are required for core regulatory transcription.	Nat Commun	2019
30698726	Pregnancy-Associated Plasma Protein-A (PAPP-A) in Ewing Sarcoma: Role in Tumor Growth and Immune Evasion.	J Natl Cancer Inst	2019
31222885	Insights into pediatric rhabdomyosarcoma research: Challenges and goals.	Pediatr Blood Cancer	2019
31431459	Targeting Glycolysis through Inhibition of Lactate Dehydrogenase Impairs Tumor Growth in Preclinical Models of Ewing Sarcoma.	Cancer Res	2019
31110075	Modulation of Target Antigen Density Improves CAR T-cell Functionality and Persistence.	Clin Cancer Res	2019
29155426	CD22-targeted CAR T cells induce remission in B-ALL that is naive or resistant to CD19-targeted CAR immunotherapy.	Nat Med	2018
29973406	MEK inhibition induces MYOG and remodels super-enhancers in RAS-driven rhabdomyosarcoma.	Sci Transl Med	2018
29972784	Integrative Bayesian Analysis Identifies Rhabdomyosarcoma Disease Genes.	Cell Rep	2018